[go: up one dir, main page]

WO2002020509A3 - Medicament pour lutter contre des maladies virales - Google Patents

Medicament pour lutter contre des maladies virales Download PDF

Info

Publication number
WO2002020509A3
WO2002020509A3 PCT/EP2001/009772 EP0109772W WO0220509A3 WO 2002020509 A3 WO2002020509 A3 WO 2002020509A3 EP 0109772 W EP0109772 W EP 0109772W WO 0220509 A3 WO0220509 A3 WO 0220509A3
Authority
WO
WIPO (PCT)
Prior art keywords
hbv
viral infections
against viral
medicaments against
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2001/009772
Other languages
German (de)
English (en)
Other versions
WO2002020509A2 (fr
Inventor
Susanne Nikolic
Stephan Bartel
Michael Brands
Ulrich Niewoehner
Arnold Paessens
Erwin Graef
Karl-Heinz Schlemmer
Kerstin Henninger
Rainer Endermann
Olaf Weber
Diana Koletzki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2000143791 external-priority patent/DE10043791A1/de
Priority claimed from DE2000154932 external-priority patent/DE10054932A1/de
Application filed by Bayer AG filed Critical Bayer AG
Priority to AU2001289831A priority Critical patent/AU2001289831A1/en
Publication of WO2002020509A2 publication Critical patent/WO2002020509A2/fr
Publication of WO2002020509A3 publication Critical patent/WO2002020509A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/96—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings spiro-condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Des dérivés de chromanone sont des agents antiviraux hautement efficaces. Des combinaisons de chromanones et/ou de chromanoles avec des inhibiteurs de la polymérase du HBV, des inhibiteurs de la protéine du HBV-de l'ADN voire des inhibiteurs de la protéine du noyau HBV et/ou des isoxazoles, ainsi qu'éventuellement avec l'interféron inhibent mieux la multiplication des virus HBV que les agents connus jusqu'à présent.
PCT/EP2001/009772 2000-09-06 2001-08-24 Medicament pour lutter contre des maladies virales Ceased WO2002020509A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001289831A AU2001289831A1 (en) 2000-09-06 2001-08-24 Medicaments against viral infections

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10043791.5 2000-09-06
DE2000143791 DE10043791A1 (de) 2000-09-06 2000-09-06 Arzneimittel gegen virale Erkrankungen
DE2000154932 DE10054932A1 (de) 2000-11-06 2000-11-06 Arzneimittelkombinationen gegen virale Erkrankungen
DE10054932.2 2000-11-06

Publications (2)

Publication Number Publication Date
WO2002020509A2 WO2002020509A2 (fr) 2002-03-14
WO2002020509A3 true WO2002020509A3 (fr) 2002-06-27

Family

ID=26006936

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/009772 Ceased WO2002020509A2 (fr) 2000-09-06 2001-08-24 Medicament pour lutter contre des maladies virales

Country Status (3)

Country Link
US (1) US20020082264A1 (fr)
AU (1) AU2001289831A1 (fr)
WO (1) WO2002020509A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8093389B2 (en) 2007-01-12 2012-01-10 Merck Sharp & Dohme Corp. Substituted spirochromanone derivatives

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2450006C2 (ru) * 2006-04-18 2012-05-10 Эбботт Лэборетриз Антагонисты ванилоидного рецептора подтипа 1(vr1) и их применение
AP2009004880A0 (en) * 2006-11-29 2009-06-30 Pfizer Prod Inc Spiroketone acetyl-COA carboxylase inhibitors
US8138197B2 (en) * 2007-01-12 2012-03-20 Msd K.K. Spirochromanon derivatives
WO2011140425A1 (fr) 2010-05-06 2011-11-10 Vertex Pharmaceuticals Incorporated Amides de chromène hétérocyclique-pipéridine spirocyclique utiles comme modulateurs des canaux ioniques
CN102558126B (zh) * 2010-12-16 2014-03-05 复旦大学 2-取代色原酮类化合物及其制备方法和用途
CN106008504A (zh) 2011-02-02 2016-10-12 沃泰克斯药物股份有限公司 作为离子通道调节剂的吡咯并吡嗪-螺环哌啶酰胺
CA2827311A1 (fr) 2011-02-18 2012-08-23 Vertex Pharmaceuticals Incorporated Amides de piperidine spirocyclique chromanique en tant que modulateurs des canaux ioniques
AU2012229187B2 (en) 2011-03-14 2016-11-10 Vertex Pharmaceuticals Incorporated Morpholine-spirocyclic piperidine amides as modulators of ion channels
WO2015151001A1 (fr) 2014-03-29 2015-10-08 Lupin Limited Composés sulfonamides comme modulateurs des canaux sodiques potentiel-dépendants
CN104262317B (zh) * 2014-09-04 2016-08-17 玉溪师范学院 一种二聚单萜类化合物及其制备方法与应用
CN107311973B (zh) * 2017-06-25 2021-04-06 石家庄学院 一种含硝酸酯基二氢杨梅素衍生物及其制备和应用
WO2025015178A1 (fr) * 2023-07-11 2025-01-16 Pretzel Therapeutics, Inc. Modulateurs de la réplication d'adn mitochondrial

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2611910A1 (de) * 1976-03-20 1977-09-22 Bayer Ag Chromanone-(4)
EP0004624A2 (fr) * 1978-04-07 1979-10-17 Bayer Ag Dérivés de chromanones, procédé pour leur préparation et leur utilisation comme médicaments et promoteurs de croissance
WO1995030642A1 (fr) * 1994-05-06 1995-11-16 Pharmacopeia, Inc. Bibliotheque combinatoire de dihydrobenzopyranes
EP0695547A1 (fr) * 1993-04-09 1996-02-07 Toyama Chemical Co., Ltd. Immunomodulateur, inhibiteur de l'adherence cellulaire, et agent permettant de traiter et de prevenir des maladies auto-immunes
US6005103A (en) * 1993-11-19 1999-12-21 Warner-Lambert Company Pyrone derivatives as protease inhibitors and antiviral agents
US6046355A (en) * 1996-11-01 2000-04-04 Warner-Lambert Company Dihydropyrones with improved antiviral activity

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2611910A1 (de) * 1976-03-20 1977-09-22 Bayer Ag Chromanone-(4)
EP0004624A2 (fr) * 1978-04-07 1979-10-17 Bayer Ag Dérivés de chromanones, procédé pour leur préparation et leur utilisation comme médicaments et promoteurs de croissance
EP0695547A1 (fr) * 1993-04-09 1996-02-07 Toyama Chemical Co., Ltd. Immunomodulateur, inhibiteur de l'adherence cellulaire, et agent permettant de traiter et de prevenir des maladies auto-immunes
US6005103A (en) * 1993-11-19 1999-12-21 Warner-Lambert Company Pyrone derivatives as protease inhibitors and antiviral agents
WO1995030642A1 (fr) * 1994-05-06 1995-11-16 Pharmacopeia, Inc. Bibliotheque combinatoire de dihydrobenzopyranes
US6046355A (en) * 1996-11-01 2000-04-04 Warner-Lambert Company Dihydropyrones with improved antiviral activity

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHIN-TENG CHANG ET AL.: "Coumarins and Anti-HBV constizuents from Zanthoxylum Schinifolium", PHYTOCHEMISTRY., vol. 45, no. 7, 1997, PERGAMON PRESS., GB, pages 1419 - 1422, XP004293278, ISSN: 0031-9422 *
STEVE R. TURNER ET AL.: "Tipranavir(PNU-140690) A potent, Orally Bioavailable Nonpeptidic HIV protease inhibitor of the 5,6-Dihydro-4-hydroxy-2-pyrone Sulfonamide Class", JOURNAL OF MEDICINAL CHEMISTRY., vol. 41, no. 18, 1998, AMERICAN CHEMICAL SOCIETY., US, pages 3467 - 3476, XP002194391, ISSN: 0022-2623 *
SUVIT THAISRIVONGS ET AL.: "Structure-based design of Hiv protease Inhibitors: 5,6-Dihydro-4-hydroxy-2-pyrones as effective, nonpeptidic Inhibitors", JOURNAL OF MEDICINAL CHEMISTRY., vol. 39, no. 23, 1996, AMERICAN CHEMICAL SOCIETY., US, pages 4630 - 4642, XP002194392, ISSN: 0022-2623 *
ZE-QI XU ET AL.: "In Vitro Anti-Human Immunodeficiency Virus Activity of the chromanone derivative, 12-oxocalanolide A, a novel NNRTI", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, no. 8, 1998, OXFORD, GB, pages 2179 - 2184, XP004137242, ISSN: 0960-894X *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8093389B2 (en) 2007-01-12 2012-01-10 Merck Sharp & Dohme Corp. Substituted spirochromanone derivatives

Also Published As

Publication number Publication date
US20020082264A1 (en) 2002-06-27
AU2001289831A1 (en) 2002-03-22
WO2002020509A2 (fr) 2002-03-14

Similar Documents

Publication Publication Date Title
WO2001077091A3 (fr) Inhibiteurs de polymerases ns5b vhc
WO2002020509A3 (fr) Medicament pour lutter contre des maladies virales
PL378354A1 (pl) Analogi nukleozydów przeciwwirusowych i sposoby leczenia zakażeń wirusowych, zwłaszcza zakażeń wirusem HIV
WO2004011478A3 (fr) Nucleosides d de 7-deaza antiviraux et leurs utilisations
DK1265889T3 (da) Lægemidler imod virussygdomme
IL215891A (en) Hepatitis C Serine Protease Inhibitors, Pharmaceutical Compounds Containing Them, and Their Use in Preparing Drugs to Treat Hepatitis C Infections
WO2002057287A3 (fr) Derives de nucleoside servant d'inhibiteurs de l'arn polymerase virale arn dependante
WO2007001406A3 (fr) Composes macrocycliques contenant un aryle
AU2002364730A1 (en) N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections
WO2001003681A3 (fr) Utilisation de flavones, de coumarines et de composes associes dans le traitement d'infections
WO2004007512A3 (fr) Derives de nucleosides utilises en tant qu'inhibiteurs de l'arn polymerase virale arn-dependante
WO2004000858A3 (fr) Derives nucleosidiques utilises comme inhibiteurs de l'arn polymerase virale arn-dependante
WO2004003138A3 (fr) Derives nucleosidiques utilises comme inhibiteurs de l'arn polymerase arn-dependante virale
EP1673385A4 (fr) Peptides macrocycliques actifs contre le virus de l'hepatite c
WO2008003149A3 (fr) Ptéridines substituées pour le traitement et la prévention d'infections virales
WO2007049265A3 (fr) Therapie antimineralocorticoidique contre une infection
WO2005013917A3 (fr) Therapie combinee servant a traiter une infection par un alphavirus et une fibrose hepatique
EP1256348A4 (fr) Remedes contre l'hepatite c
WO2006101538A3 (fr) Derives d'andrographolide servant a traiter les infections virales
WO2001012228A3 (fr) Compositions pour le traitement des infections virales, et procedes correspondants
AU2003249659A1 (en) Combination therapy for rna virus infections involving ribavirin and impdh inhibitors
WO2003025139A3 (fr) Administration d'acides nucleiques, d'analogues et de derives de ceux-ci induite par cobalamine
DE60021413D1 (de) Anti-virale zusammensetzung enthaltend ein palmaria palmata extrakt
WO2002000613A3 (fr) Inhibiteurs d'infections par le virus de l'hepatite b (vhb)
TR200201954T2 (tr) Viral hastalıklar için tıbbi maddeler.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP